Trimetrexate for the Treatment of Pneumocystis carinii Pneumonia in Patients with the Acquired Immunodeficiency Syndrome

Preclinical studies have demonstrated that trimetrexate is a potent inhibitor of dihydrofolate reductase from Pneumocystis carinii . On the basis of this evidence, this lipid-soluble antifolate was used as an antipneumocystis agent in 49 patients with the acquired immunodeficiency syndrome (AIDS) an...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 1987-10, Vol.317 (16), p.978-985
Hauptverfasser:	Allegra, Carmen J, Chabner, Bruce A, Tuazon, Carmelita U, Ogata-Arakaki, Debra, Baird, Barbara, Drake, James C, Simmons, J. Thayer, Lack, Ernest E, Shelhamer, James H, Balis, Frank, Walker, Robert, Kovacs, Joseph A, Lane, H. Clifford, Masur, Henry
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired Immunodeficiency Syndrome - complications Adult Antibiotics. Antiinfectious agents. Antiparasitic agents Antiparasitic agents Biological and medical sciences Dihydrofolate reductase Drug Evaluation Drug Therapy, Combination FDA approval Female Folic Acid Antagonists - administration & dosage Folic Acid Antagonists - therapeutic use Humans Leucovorin - administration & dosage Male Medical sciences Middle Aged Organisms Pharmacology. Drug treatments Pneumonia Pneumonia, Pneumocystis - drug therapy Quinazolines - administration & dosage Quinazolines - adverse effects Quinazolines - pharmacokinetics Sulfadiazine - administration & dosage Trimetrexate
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!